IL13RA2 and glioblastoma: Clinical trials are starting to look into the safety of this dual therapy in patients with GBM, using CAR T cells against EGFRvIII along with Pembrolizumab (NCT03726515) and CAR T cells targeting IL13Rα2 along with Nivolumab or Ipilimumab (NCT04003649).